NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
NeuroPace (NPCE) announced it will present three-year data from its Post-Approval Study (PAS) of the RNS® System at the 2025 American Academy of Neurology Annual Meeting in San Diego. The presentation will focus on results in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy (DRE).
The RNS System, the first and only neuromodulation platform delivering personalized, real-time seizure treatment, will be showcased at booth #1642. Key presentations include an oral session on April 7 by Dr. Dawn Eliashiv, an Exhibitor Hall presentation on April 8 by Dr. Martha Morrell and Dr. Barbara Jobst, and encore webinars on April 8 and 11 for those unable to attend in person.
NeuroPace (NPCE) ha annunciato che presenterà i dati di tre anni del suo Studio Post-Approvazione (PAS) sul RNS® System durante il Congresso Annuale dell'Accademia Americana di Neurologia del 2025 a San Diego. La presentazione si concentrerà sui risultati in adulti trattati con stimolazione reattiva al cervello per l'epilessia focale resistente ai farmaci (DRE).
Il RNS System, la prima e unica piattaforma di neuromodulazione che offre un trattamento personalizzato e in tempo reale delle crisi, sarà esposto allo stand #1642. Le presentazioni chiave includono una sessione orale il 7 aprile a cura della Dr.ssa Dawn Eliashiv, una presentazione nell'Exhibitor Hall l'8 aprile a cura della Dr.ssa Martha Morrell e della Dr.ssa Barbara Jobst, e webinar ripetuti l'8 e l'11 aprile per coloro che non possono partecipare di persona.
NeuroPace (NPCE) anunció que presentará datos de tres años de su Estudio Post-Aprobación (PAS) sobre el RNS® System en la Reunión Anual de la Academia Americana de Neurología 2025 en San Diego. La presentación se centrará en los resultados en adultos tratados con estimulación cerebral responsiva para la epilepsia focal resistente a medicamentos (DRE).
El RNS System, la primera y única plataforma de neuromodulación que ofrece tratamiento personalizado y en tiempo real para las crisis, se exhibirá en el stand #1642. Las presentaciones clave incluyen una sesión oral el 7 de abril por la Dra. Dawn Eliashiv, una presentación en el Exhibitor Hall el 8 de abril por la Dra. Martha Morrell y la Dra. Barbara Jobst, y seminarios web adicionales el 8 y el 11 de abril para aquellos que no puedan asistir en persona.
NeuroPace (NPCE)는 2025년 샌디에이고에서 열리는 미국 신경학회 연례 회의에서 RNS® 시스템의 사후 승인 연구(PAS) 3년 데이터를 발표할 것이라고 발표했습니다. 발표는 약물 저항성 국소 간질(DRE) 치료를 받은 성인의 결과에 중점을 둘 것입니다.
RNS 시스템은 개인화된 실시간 발작 치료를 제공하는 최초이자 유일한 신경 조절 플랫폼으로, 부스 #1642에서 전시될 예정입니다. 주요 발표로는 4월 7일 Dawn Eliashiv 박사의 구술 세션, 4월 8일 Martha Morrell 박사와 Barbara Jobst 박사의 전시 홀 발표, 그리고 직접 참석할 수 없는 분들을 위한 4월 8일과 11일의 재방송 웨비나가 포함됩니다.
NeuroPace (NPCE) a annoncé qu'il présentera des données de trois ans de son Étude Post-Approbation (PAS) sur le RNS® System lors de la Réunion Annuelle de l'Académie Américaine de Neurologie en 2025 à San Diego. La présentation se concentrera sur les résultats chez les adultes traités par stimulation cérébrale réactive pour l'épilepsie focale résistante aux médicaments (DRE).
Le RNS System, la première et unique plateforme de neuromodulation offrant un traitement personnalisé et en temps réel des crises, sera exposé au stand #1642. Les présentations clés incluent une session orale le 7 avril par Dr. Dawn Eliashiv, une présentation dans le Hall des Exposants le 8 avril par Dr. Martha Morrell et Dr. Barbara Jobst, ainsi que des webinaires supplémentaires le 8 et le 11 avril pour ceux qui ne peuvent pas assister en personne.
NeuroPace (NPCE) hat angekündigt, dass es auf dem Jahrestreffen der American Academy of Neurology 2025 in San Diego Daten aus seiner dreijährigen Nachgenehmigungsstudie (PAS) zum RNS® System präsentieren wird. Der Schwerpunkt der Präsentation liegt auf den Ergebnissen bei Erwachsenen, die mit hirnreaktiver Stimulation gegen medikamentenresistente fokale Epilepsie (DRE) behandelt wurden.
Das RNS System, die erste und einzige Neuromodulationsplattform, die personalisierte, Echtzeit-Behandlung von Anfällen bietet, wird am Stand #1642 vorgestellt. Zu den wichtigen Präsentationen gehören eine mündliche Sitzung am 7. April von Dr. Dawn Eliashiv, eine Präsentation im Ausstellerbereich am 8. April von Dr. Martha Morrell und Dr. Barbara Jobst sowie Wiederholungs-Webinare am 8. und 11. April für diejenigen, die nicht persönlich teilnehmen können.
- First and only neuromodulation platform for personalized seizure treatment
- Addressing significant unmet medical need in drug-resistant focal epilepsy
- None.
Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentation
MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9. This includes an oral presentation on data from the Post-Approval Study (PAS) of the RNS® System in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy (DRE) on Monday, April 7.
“Drug-resistant focal epilepsy means patients do not respond to drug therapy and often face a lifetime of debilitating seizures from the time of childhood or adolescence,” said Joel Becker, NeuroPace’s Chief Executive Officer. “It remains a significant unmet medical need, and we are committed to helping people with DRE. We look forward to sharing insights and presenting data that may have an impact on this patient population at AAN 2025.”
The RNS System is the first and only neuromodulation platform that delivers personalized, real-time seizure treatment and will be on display in booth #1642. NeuroPace presentations and activities at the 2025 AAN Annual Meeting include:
- Oral Presentation: Multicenter Post-Approval Study of the RNS System in Focal Epilepsy
- Monday, April 7 5:06 – 5:18PM PDT | SDCC Room 29A
- Presented by Dawn Eliashiv, MD, FAAN, UCLA
- Presentation of the PAS Study at the Exhibitor Hall Stage
- Tuesday, April 8 12:00 – 12:20PM PDT | Exhibitor Presentation Stage Aisle 2100
- Presented by Martha Morrell, MD, Chief Medical Officer, NeuroPace, and Barbara Jobst, MD, Dartmouth
- Encore Presentations: Multicenter Post-Approval Study of the RNS System in Focal Epilepsy
- Clinicians unable to attend the AAN meeting in person can join an encore webinar
- Tuesday, April 8 at 8:00AM PDT and Friday, April 11 at 12:00PM PDT
- Presented by Martha Morrell, MD and Dawn Eliashiv, MD
- Register here
For more information on NeuroPace and the RNS System, join us at booth #1642 at the 2025 AAN Annual Meeting or visit https://www.neuropace.com.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: NeuroPace’s assessments about the value of the PAS data, including, but not limited to, the value of the data to physicians and their ability to effectively utilize the RNS System to treat patients with DRE focus epilepsy; the potential of the RNS System to continue to offer safe and effective treatment for larger segments of the total addressable market of DRE focal patients; current expectations, forecasts and beliefs; future financial performance, including management’s outlook for fiscal year 2025; the Company’s commitment to effectively managing its operating expenses; ability to capitalize on increased market opportunities by expanding access to treatments; and clinical trial results and indication expansion. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties related to market acceptance and adoption of NeuroPace’s RNS System; risks related to the pricing of the RNS System and availability of adequate reimbursement for the procedures to implant the RNS System and for clinicians to provide ongoing care for patients treated with the RNS System; the risk that NeuroPace may not realize the intended benefits of its partnership with DIXI Medical; risks related to regulatory compliance and expectations for regulatory approvals to expand the market for NeuroPace’s RNS System; NeuroPace’s reliance on contractors and other third parties, including single-source suppliers and vendors; and other important factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 5, 2025, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.
Contact:
Katie Keller
Vice President of Marketing, NeuroPace
kkeller@neuropace.com
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
What data will NeuroPace (NPCE) present at the 2025 AAN Annual Meeting?
When and where will NeuroPace's RNS System data be presented at AAN 2025?
What is unique about NeuroPace's RNS System for epilepsy treatment?
How can investors access NeuroPace's RNS System presentation if they can't attend AAN 2025?
